The FDA approval of imatinib in 2001 was a breakthrough in molecularly targeted cancer
therapy and heralded the emergence of kinase inhibitors as a key drug class in the oncology …

Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular
processes. Deregulation of FGFR signalling is observed in a subset of many cancers …

The human genome encodes 538 protein kinases that transfer a γ-phosphate group from
ATP to serine, threonine, or tyrosine residues. Many of these kinases are associated with …

Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …

Many human malignancies are associated with aberrant regulation of protein or lipid
kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein …

Lung cancer has a high prevalence, with a growing number of new cases and mortality
every year. Furthermore, the survival rate of patients with non-small-cell lung carcinoma …

Deregulation of kinase activity has emerged as a major mechanism by which cancer cells
evade normal physiological constraints on growth and survival. To date, 11 kinase inhibitors …

The development and clinical application of inhibitors that target the epidermal growth factor
receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the …

Background Lung adenocarcinomas from patients who respond to the tyrosine kinase
inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function …

Lung cancer remains one of the leading causes of cancer-related death in developed
countries. Although lung adenocarcinomas with EGFR mutations or EML4-ALK fusions …